These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33115684)

  • 1. COVID-19, steroids and other immunomodulators: The jigsaw is not complete.
    Rello J; Waterer GW; Bourdiol A; Roquilly A
    Anaesth Crit Care Pain Med; 2020 Dec; 39(6):699-701. PubMed ID: 33115684
    [No Abstract]   [Full Text] [Related]  

  • 2. [Corticosteroids in intensive care medicine].
    Sensen B; Nierhaus A; Kluge S
    Dtsch Med Wochenschr; 2024 Jun; 149(12):714-718. PubMed ID: 38781995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for hospitalized patients with COVID-19.
    Afra K; Chen LYC; Sweet D
    CMAJ; 2021 Apr; 193(15):E521. PubMed ID: 33692091
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.
    Ye Z; Wang Y; Colunga-Lozano LE; Prasad M; Tangamornsuksan W; Rochwerg B; Yao L; Motaghi S; Couban RJ; Ghadimi M; Bala MM; Gomaa H; Fang F; Xiao Y; Guyatt GH
    CMAJ; 2020 Jul; 192(27):E756-E767. PubMed ID: 32409522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of High-Dose Corticosteroids Versus Low-Dose Corticosteroids With and Without Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
    Katz A; Altshuler D; Papadopoulos J; Amoroso N; Goldenberg R; Tarras E; Krolikowski K; Hagedorn J; Fridman D; Chen XJC; Iturrate E; Brosnahan SB
    Ann Pharmacother; 2023 Jan; 57(1):5-15. PubMed ID: 35590468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Audio Interview: Tocilizumab and Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
    [No Abstract]   [Full Text] [Related]  

  • 7. High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial.
    Maskin LP; Olarte GL; Palizas F; Velo AE; Lurbet MF; Bonelli I; Baredes ND; Rodríguez PO
    Trials; 2020 Aug; 21(1):743. PubMed ID: 32843098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view.
    Berton AM; Prencipe N; Giordano R; Ghigo E; Grottoli S
    J Endocrinol Invest; 2021 Apr; 44(4):873-875. PubMed ID: 32514902
    [No Abstract]   [Full Text] [Related]  

  • 9. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
    Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
    Pandolfi L; Fossali T; Frangipane V; Bozzini S; Morosini M; D'Amato M; Lettieri S; Urtis M; Di Toro A; Saracino L; Percivalle E; Tomaselli S; Cavagna L; Cova E; Mojoli F; Bergomi P; Ottolina D; Lilleri D; Corsico AG; Arbustini E; Colombo R; Meloni F
    BMC Pulm Med; 2020 Nov; 20(1):301. PubMed ID: 33198751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
    Miao Y; Fan L; Li JY
    Front Immunol; 2020; 11():1445. PubMed ID: 32612616
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series.
    Nakamura H; Miyagi K; Otsuki M; Higure Y; Nishiyama N; Kinjo T; Nakamatsu M; Haranaga S; Tateyama M; Fujita J
    Respir Investig; 2020 Nov; 58(6):510-512. PubMed ID: 33067149
    [No Abstract]   [Full Text] [Related]  

  • 13. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
    Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
    Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab prescribing criteria for COVID-19 patients.
    Al-Qaaneh AM; Al-Ghamdi FH
    Hum Vaccin Immunother; 2021 Apr; 17(4):1128. PubMed ID: 33079613
    [No Abstract]   [Full Text] [Related]  

  • 15. COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- A retrospective observational study.
    Longobardo A; Snow TAC; Montanari C; Shulman R; Singer M; Arulkumaran N
    J Crit Care; 2021 Apr; 62():46-48. PubMed ID: 33260010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.
    Kumar S; De Souza R; Nadkar M; Guleria R; Trikha A; Joshi SR; Loganathan S; Vaidyanathan S; Marwah A; Athalye SN
    Expert Opin Biol Ther; 2021 May; 21(5):675-686. PubMed ID: 33835886
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial.
    Villar J; Añón JM; Ferrando C; Aguilar G; Muñoz T; Ferreres J; Ambrós A; Aldecoa C; Suárez-Sipmann F; Thorpe KE; Jüni P; Slutsky AS;
    Trials; 2020 Aug; 21(1):717. PubMed ID: 32799933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The COVID-19 Cytokine Storm; What We Know So Far.
    Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
    Front Immunol; 2020; 11():1446. PubMed ID: 32612617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome.
    Segú-Vergés C; Artigas L; Coma M; Peck RW
    PLoS One; 2023; 18(2):e0280677. PubMed ID: 36791125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.